Kynam Capital Management, LP
Position in CLDX — Celldex Therapeutics, Inc.
CIK 1907884
PRINCETON, NJ
Position in CLDX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$198,065,406
+$12,802,621 QoQ
Shares Held
5,322,908
-8.9% QoQ
Ownership
6.78%
of shares outstanding
% of Portfolio
10.95%
of 13F equity value
Holder Rank
#3
of 252 holders
Holding Since
Dec 2021
19 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CLDX Over Time
Shares Held
Position Value (USD)
Derivatives in CLDX
reported options exposure · as of Jun 30, 2022CallValue
$6,642,944
CallShares
246,400
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Kynam Capital Management, LP holds $1,765,169,848 across 29 Biotechnology names. CLDX ranks #1 (11.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CLDX |
Celldex Therapeutics, Inc.
This page
|
5,322,908 | $198,065,406 | |
| 2 | SNDX |
Syndax Pharmaceuticals Inc
|
8,050,959 | $175,993,963 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
2,922,335 | $169,875,333 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
3,667,097 | $141,916,653 | |
| 5 | VERA |
Vera Therapeutics, Inc.
|
2,890,059 | $124,012,431 | |
| 6 | VRDN |
Viridian Therapeutics, Inc.\DE
|
6,453,877 | $118,557,720 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
2,000,000 | $113,620,000 | |
| 8 | BEAM |
Beam Therapeutics Inc.
|
2,840,792 | $97,495,981 |
All Filings in CLDX
Export CSV
22 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $198,065,406 | 5,322,908 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $0 | 0 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $185,262,785 | 5,840,567 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $161,416,768 | 5,943,180 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $157,825,859 | 6,100,729 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $124,149,835 | 6,100,729 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $117,975,000 | 6,500,000 | Shares | Sole | 2025-05-15 | |
| 2025-03-31 | $117,975,000 | 6,500,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $127,972,510 | 5,064,207 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $117,558,119 | 3,458,609 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $125,425,668 | 3,388,967 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $121,713,000 | 2,900,000 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $119,214,152 | 3,005,904 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $88,064,000 | 3,200,000 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $88,218,000 | 2,600,000 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $50,712,046 | 1,409,451 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $71,552,232 | 1,605,390 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $44,979,569 | 1,600,127 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $30,525,702 | 1,132,259 | Shares | Sole | 2022-08-15 | |
| 2022-06-30 | $6,642,944 | 246,400 | Call | Sole | 2022-08-15 | |
| 2022-03-31 | $25,648,338 | 753,034 | Shares | Sole | 2022-05-13 | |
| 2021-12-31 | $8,760,692 | 226,726 | Shares | Sole | 2022-02-14 | |
| No filing history on record for this holder in this stock. | ||||||